Saturday, July 11, 2026

pharma · Schizophrenia

Shanghai Mental Health

Shanghai Mental Health is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this en

Shanghai, CN HQ
1958 Founded
97 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Shanghai, CN
Founded
1958
Employees
97
Programs
1
Drugs
2
Patents
0

Quick answer

Shanghai Mental Health is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

Company snapshot

The Shanghai Mental Health Center (SMHC), formerly known as the Shanghai Psychiatric Hospital, was founded in 1958. Its predecessor, Mercy Hospital, was established in 1935. The SMHC is consist of a main hospital(in Xuhui district) and a branch hospital (in Minhang district). SMHC has numerous functions. In addition to serving as a mental health clinic offering medication management and psychother

  • 1 active pipeline program(s) linked via ClinicalTrials.gov.
  • 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Shanghai Mental Health. Not investment advice.

Active clinical programs

Momentum signals

Momentum

Proprietary activity score for Shanghai Mental Health.

1 active signal

7 /100 +0 vs 30 days ago

Signal breakdown

  • Clinical trials 1 30d
  • Nova articles 0 30d
  • Patents filed 0 30d
  • FDA actions 0 30d
  • SEC filings 0 30d
  • Conference presentations 0 90d
  • Pipeline advances 0 30d
Competitive landscape
Recent activity

Recent activity

Latest pipeline, patent, and corporate events for Shanghai Mental Health.

  1. Clinical update

    Phase 1: Olanzapine — Phase 3

View all clinical trial activity →

Quick answers

Common questions about this sponsor — for analysts and search.

  • What is Shanghai Mental Health?

    Shanghai Mental Health is a pharma organization headquartered in CN. Primary therapeutic focus areas include Schizophrenia. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sou

  • Is Shanghai Mental Health publicly traded?

    Shanghai Mental Health appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

  • What drugs does Shanghai Mental Health develop or market?

    We link 2 drug profile(s) where Shanghai Mental Health is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/shanghai-mental-health-center#company-drugs.

  • What are the latest developments for Shanghai Mental Health?

    In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

  • What therapeutic areas does Shanghai Mental Health focus on?

    Shanghai Mental Health focuses on Schizophrenia based on our analysis of their pipeline programs and drug development activities.

Therapeutic focus

Therapeutic area distribution

Pipeline concentration by therapeutic area from linked clinical programs.

Programs by therapeutic area

Others
2
Neurology
1